INO - Inovio Pharmaceuticals, Inc.
After hours:
Chart Events
Hammer
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.6199 |
| Open | 0.6132 |
| Bid | 0.6142 x 3000 |
| Ask | 0.6200 x 1100 |
| Day's Range | 0.5950 - 0.6208 |
| 52 Week Range | 0.5800 - 2.8200 |
| Volume | |
| Avg. Volume | 6,267,037 |
| Market Cap | 162.925M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9700 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.33 |
Fair Value
Related Research
PR NewswireINOVIO to Present at the 2023 Jefferies Healthcare Conference
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO, and Dr. Michael Sumner, CMO, will present at the 2023 Jefferies Healthcare Conference.
PR NewswireINOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Commission (EC) has granted orphan drug designation for INO-3107, the company's product candidate for the treatment of Recurrent Respiratory Papillomatosis (RRP). INO-3107 is an investigational DNA medicine candidate designed to elicit a targeted T cell response against H
ZacksAll You Need to Know About Inovio (INO) Rating Upgrade to Buy
Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Simply Wall St.These Analysts Think Inovio Pharmaceuticals, Inc.'s (NASDAQ:INO) Sales Are Under Threat
The analysts covering Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ) delivered a dose of negativity to shareholders today...
- Simply Wall St.
Analysts Have Lowered Expectations For Inovio Pharmaceuticals, Inc. (NASDAQ:INO) After Its Latest Results
As you might know, Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ) last week released its latest first-quarter, and things...
- Simply Wall St.
Inovio Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations
Inovio Pharmaceuticals ( NASDAQ:INO ) First Quarter 2023 Results Key Financial Results Revenue: US$114.9k (down 42...
Motley FoolInovio Pharmaceuticals (INO) Q1 2023 Earnings Call Transcript
Good afternoon and thank you for joining the Inovio 2023 first quarter conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO; Dr. Michael Sumner, chief medical officer; and Mr.
ZacksInovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireINOVIO Reports First Quarter 2023 Financial Results and Operational Highlights
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced financial results and operational highlights for the first quarter of 2023. INOVIO's management will host its quarterly conference call and webcast today at 4:30 p.m. EDT. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentati
PR NewswireNew Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Me
PR NewswireINOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the 2023 RBC Capital Markets Global Healthcare Conference.
PR NewswireINOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2023 financial results will be released after the market close on May 10, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.
PR NewswireINOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) at this year's American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts
PR NewswireEuropean Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Committee for Orphan Medicinal Products (COMP) has provided a positive opinion on INOVIO's application for orphan drug designation in the European Union (EU) for INO-3107. INO-3107 is the company's product candidate that may contribute to the treatment of Recurrent Respi
Motley FoolThese 3 Nasdaq Stocks Are on Fire Today: Here's Why
What happened Biopharmaceutical stocks were trending higher across the board Monday morning, thanks to Merck's (NYSE: MRK) nearly $11 billion buyout offer for Prometheus Biosciences (NASDAQ: RXDX). So far, some of the day's biggest winners have been the cancer immunotherapy specialist Agenus (NASDAQ: AGEN), the next-generation vaccine player Inovio Pharmaceuticals (NASDAQ: INO), and the drug developer Roivant Sciences (NASDAQ: ROIV).
PR NewswireData from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that data from a Phase 1b trial evaluating INO-4201 as an Ebola booster vaccine candidate for rVSV-ZEBOV (Ervebo) (NCT04906629) was presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Dr. Angela Huttner, Infectious Disease Consultant, Gene
Motley FoolWhy Inovio Pharmaceuticals' Shares Jumped on Thursday
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were up 20% early Thursday afternoon after the biotech company announced that it will present its abstract for INO-4201 as an Ebola booster for rVSV-ZEBOV (Ervebo) at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) on Sunday. Inovio mainly focuses on DNA medicines to treat people with human papillomavirus (HPV) diseases, cancer, and infectious diseases. The main concern with Inovio is the company lost $279.8 million last year and says it has only enough cash -- $253 million -- to last into the first quarter of 2025.
PR NewswireINOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for presentation for INO-4201 as an Ebola booster for rVSV-ZEBOV (Ervebo) at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Motley FoolWhy Shares of Inovio Pharmaceuticals Were Down Tuesday
Shares of Inovio Pharmaceuticals (NASDAQ: INO) were down more than 10% on Tuesday afternoon, falling to a 52-week low of $0.07036 a share at one point. The biotechnology company specializes in developing DNA medicines to treat people with human papillomavirus (HPV) diseases, cancer, and infectious diseases. When the company announced on Monday that it was offering Dr. Cheryl Elder, its newly hired senior vice president for regulatory affairs, stock options under its 2022 Inducement Plan, the stock dropped again.
PR NewswireINOVIO Reports Inducement Grant Under Inducement Plan
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to its newly hired Senior Vice President, Regulatory Affairs under its 2022 Inducement Plan (the "Inducement Plan").
Insider MonkeyInovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. Please note, this event is being recorded. I would now like to turn the conference over to Thomas Hong, Manager of Investor Relations. Please go ahead. Thomas […]
PR NewswireINOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference.
- Motley Fool
Inovio Pharmaceuticals (INO) Q4 2022 Earnings Call Transcript
Good afternoon, and thank you for joining the Inovio 2022 fourth quarter and full year financial results conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO and Dr. Michael Sumner, chief medical officer; and Mr. Today's call will review our corporate and financial information for the quarter and year ended December 31st, 2022, as well as provide an update on our efforts to develop our DNA medicines platform.
ZacksInovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates
Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
PR NewswireINOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today reported financial results for the quarter and year ended December 31, 2022, and provided a business update. INOVIO's management will host a live conference call and webcast with slides at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update for the fourth
